Drugs / Oxytocin
last change 3 days ago re-read 2 minutes ago

Oxytocin

Peptide targets OXTR

Developed for
schizophrenia · autism spectrum disorder · post-traumatic stress disorder · alcohol-related disorders · chronic pain syndrome · uterine disorder · alcohol dependence · obesity disorder
+88 more · osteoarthritis, knee · Prader-Willi syndrome · dystocia · postmenopausal atrophic vaginitis · pregnancy disorder · substance abuse · autism · cervix disorder · cocaine dependence · preterm premature rupture of the membranes · autism spectrum disorder 1 · CGF1 · frontotemporal dementia · obstructive sleep apnea syndrome · opiate dependence · schizoaffective disorder · social phobia · anxiety disorder · borderline personality disorder · depressive disorder · disruptive behavior disorder · drug dependence · neurohypophyseal diabetes insipidus · nicotine dependence · obesity, hyperphagia, and developmental delay · postpartum depression · preeclampsia · substance withdrawal syndrome · substance-related disorder · tinnitus · acquired hypothalamic obesity · adenomyosis · alcohol withdrawal · amphetamine abuse · anemia · antisocial personality disorder · anxiety · binge eating disorder · body dysmorphic disorder · cardiac rhythm disease · childhood-onset schizophrenia · cocaine abuse · COVID-19 · diabetes mellitus · disease of bone structure · dyspepsia · dysthymic disorder · eating disorder · Ehlers-Danlos syndrome, hypermobility type · female infertility · fragile X syndrome · functional gastric disease · headache disorder · hemorrhagic disease · infertility disorder · leiomyoma · major depressive disorder · migraine with aura · migraine without aura · mood disorder · myocardial infarction · neuropathy, painful · newborn respiratory distress syndrome · obsessive-compulsive disorder · paranoid personality disorder · pelvis syndrome · perinatal disease · Phelan-McDermid syndrome · placenta accreta · placenta disorder · polycystic ovary syndrome · premenstrual dysphoric disorder · psychotic disorder · sunburn · toxic or drug-related embryofetopathy · uterine corpus leiomyoma · alcohol abuse · bipolar disorder · cannabis dependence · central diabetes insipidus · heart disorder · interstitial cystitis · obstetric disorder · ovarian disorder · schizotypal personality disorder · severe pre-eclampsia · sexual disorder · skin atrophy
Investigated by
University of Electronic Science and Technology of China · Wake Forest University Health Sciences · Massachusetts General Hospital · University of California, San Francisco · Medical University of South Carolina · University of North Carolina, Chapel Hill
+270 more · University Hospital, Bonn · KU Leuven · National Institute of Mental Health (NIMH) · National Institute of Neurological Disorders and Stroke (NINDS) · Rambam Health Care Campus · Samuel Lunenfeld Research Institute, Mount Sinai Hospital · University Hospital, Toulouse · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · PepTonic Medical AB · Research Foundation Flanders · San Francisco Veterans Affairs Medical Center · Shalvata Mental Health Center · United States Department of Defense · University of California, Los Angeles · University of California, San Diego · University of Florida · University of Maryland, Baltimore · Yale University · Cairo University · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Northwestern University · Norwegian University of Science and Technology · Sheba Medical Center · St. Olavs Hospital · University of Chicago · VA Office of Research and Development · Assiut University · Beijing Normal University · Canadian Institutes of Health Research (CIHR) · Central Institute of Mental Health, Mannheim · Emory University · George Washington University · GlaxoSmithKline · Icahn School of Medicine at Mount Sinai · Montefiore Medical Center · National Institute of Mental Health and Neuro Sciences, India · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institute on Drug Abuse (NIDA) · Stanford University · Tel-Aviv Sourasky Medical Center · University Hospital, Gentofte, Copenhagen · University of British Columbia · University of Calgary · VA Greater Los Angeles Healthcare System · Ain Shams Maternity Hospital · Alexander Kolevzon · Assistance Publique - Hôpitaux de Paris · Baylor College of Medicine · Ben-Gurion University of the Negev · Bezmialem Vakif University · Charite University, Berlin, Germany · David Feifel · Evdokia Anagnostou · Florida Institute for Human and Machine Cognition · Gynuity Health Projects · Hadassah Medical Organization · Hebrew University of Jerusalem · Holland Bloorview Kids Rehabilitation Hospital · Jennifer Mitchell · Kanuni Sultan Suleyman Training and Research Hospital · Lade Addiction Treatment Center · MacDonald, Kai, M.D. · Monash University · Office of Naval Research (ONR) · Oxytone Bioscience BV · RWTH Aachen University · Shana McCormack, MD · Skane University Hospital · Soroka University Medical Center · The Branco Weiss Fellowship · The University of Texas Health Science Center, Houston · University Hospital, Basel, Switzerland · University of Alabama at Birmingham · University of Arizona · all 276 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) SYNTOCINON 1980-04-17 fda.gov

Trials 396 · started per year

today
US approved 1980
2
2
1
3
2
4
9
11
19
14
18
23
23
34
46
34
24
16
13
15
16
23
21
15
8
197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 033 trials
Phase 0 NCT07140237 Sep → Dec 2025 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
Phase 0 NCT07093060 Jun → Nov 2025 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
Phase 0 NCT03414112 Sep 2018 → Apr 2021 anorexia nervosa University of Minnesota Completed No outcome recorded
Phase 0 NCT03136263 Dec 2017 → Nov 2020 attention deficit-hyperactivity disorder Massachusetts General Hospital Completed No outcome recorded
Phase 0 NCT03211013 Jul 2017 → Jun 2021 post-traumatic stress disorder Palo Alto Veterans Institute for Research Completed No outcome recorded
Phase 0 NCT03085654 Mar 2017 → Mar 2018 University of Electronic Science and Technology of China Completed No outcome recorded
Phase 0 NCT03144115 Oct 2016 → Jun 2018 University of Electronic Science and Technology of China Completed No outcome recorded
Phase 0 NCT02741063 May 2016 → Jun 2019 University of Electronic Science and Technology of China Unknown No outcome recorded
Phase 0 NCT03055546 Feb 2016 → Dec 2018 University of Electronic Science and Technology of China Unknown No outcome recorded
Phase 0 NCT02469259 Feb 2016 → Feb 2018 alcohol dependence, post-traumatic stress disorder University of California, San Francisco Completed No outcome recorded
Phase 140 trials
Phase 1 NCT06332066 May 2024 Shalvata Mental Health Center Unknown No outcome recorded
Phase 1 NCT05865288 Jun 2023 → Apr 2024 eating disorder Shalvata Mental Health Center Unknown No outcome recorded
Phase 1 NCT05672667 Feb → Nov 2023 Wake Forest University Health Sciences Completed No outcome recorded
Phase 1 NCT04051619 Jan 2020 → Dec 2023 substance-related disorder Brown University Completed No outcome recorded
Phase 1 NCT04292444 Dec 2019 → May 2021 University Hospital, Bonn Unknown No outcome recorded
Phase 1 NCT04137432 Sep 2019 → Sep 2020 University Hospital, Bonn Unknown No outcome recorded
Phase 1 NCT03860233 Mar 2019 → Dec 2026 expected obstructive sleep apnea syndrome Vivek Jain Recruiting No outcome recorded
Phase 1 NCT02908126 Apr 2018 → Jun 2019 Oxytone Bioscience BV Terminated No outcome recorded
Phase 1 NCT03610919 Mar → Sep 2018 University of Electronic Science and Technology of China Unknown No outcome recorded
Phase 1 NCT03255148 Jul 2017 → May 2018 KU Leuven Completed No outcome recorded
Phase 1/29 trials
Phase 1/2 NCT05405257 May 2022 → Mar 2025 Ehlers-Danlos syndrome, hypermobility type Baylor College of Medicine Terminated No outcome recorded
Phase 1/2 NCT04306354 Sep 2018 → Apr 2020 cocaine abuse, cocaine dependence, substance withdrawal syndrome Pontifical Catholic University of Rio Grande do Sul Unknown No outcome recorded
Phase 1/2 NCT03119610 Sep 2017 → Dec 2018 muscular atrophy, obesity disorder Sara Espinoza Completed No outcome recorded
Phase 1/2 NCT03272321 Jul 2017 → May 2018 KU Leuven Completed No outcome recorded
Phase 1/2 NCT03096249 Nov 2016 → May 2017 KU Leuven Completed No outcome recorded
Phase 1/2 NCT02548728 Feb → Dec 2016 opiate dependence, substance withdrawal syndrome University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 1/2 NCT01712646 Oct 2012 → Jun 2016 childhood-onset schizophrenia National Institute of Mental Health (NIMH) Terminated No outcome recorded
Phase 1/2 NCT01856530 Jul 2012 → Aug 2013 social phobia Stefan G. Hofmann Completed No outcome recorded
Phase 1/2 NCT01548521 Jul 2011 → Feb 2012 Prader-Willi syndrome University Hospital, Toulouse Completed No outcome recorded
Phase 2111 trials
Phase 2 NCT07430228 Jul 2026 → Dec 2027 expected Wake Forest University Health Sciences Enrolling by invitation No outcome recorded
Phase 2 NCT06968481 May → Oct 2026 expected Insud Pharma Not yet recruiting No outcome recorded
Phase 2 NCT07053774 Nov 2025 → Jun 2026 Wake Forest University Health Sciences Completed No outcome recorded
Phase 2 NCT07409753 Oct 2025 → Jun 2027 expected Wake Forest University Health Sciences Recruiting No outcome recorded
Phase 2 NCT06808516 Jul 2025 → Dec 2026 expected neurohypophyseal diabetes insipidus University Hospital, Basel, Switzerland Recruiting No outcome recorded
Phase 2 NCT06945926 Jun 2025 → Jun 2026 overdue avascular necrosis, lumbar spinal stenosis, rotator cuff syndrome, spinal cord injury Zhejiang University Not yet recruiting No outcome recorded
Phase 2 NCT06676774 May 2025 → Feb 2027 expected neurohypophyseal diabetes insipidus University Hospital, Basel, Switzerland Recruiting No outcome recorded
Phase 2 NCT05488457 Jan 2025 → Dec 2026 expected University of Chicago Recruiting No outcome recorded
Phase 2 NCT04435704 Jan 2025 → Jan 2027 osteoarthritis, knee Wake Forest University Health Sciences Withdrawn No outcome recorded
Phase 2 NCT04433741 Jan → Dec 2025 chronic pain syndrome Wake Forest University Health Sciences Withdrawn No outcome recorded
Show all 111 trials opens the full record — a long page
Phase 2/310 trials
Phase 2/3 NCT06248710 Jan → Dec 2024 overdue depressive disorder, zoophilia Dr. Karin Hediger Recruiting No outcome recorded
Phase 2/3 NCT05627791 Nov 2022 → Jul 2023 postmenopausal atrophic vaginitis Department of Medical Services Ministry of Public Health of Thailand Terminated No outcome recorded
Phase 2/3 NCT05298085 Apr 2022 → Apr 2023 Prader-Willi syndrome University Hospital, Toulouse Completed No outcome recorded
Phase 2/3 NCT04903002 Apr 2022 → Mar 2026 overdue chronic pain syndrome Memorial University of Newfoundland Active not recruiting No outcome recorded
Phase 2/3 NCT05093296 Dec 2021 → Jul 2023 alcohol dependence Central Institute of Mental Health, Mannheim Completed No outcome recorded
Phase 2/3 NCT02409862 Jan → Aug 2019 University of Florida Withdrawn No outcome recorded
Phase 2/3 NCT03819231 Oct 2018 → Dec 2023 University of Southern California Terminated No outcome recorded
Phase 2/3 NCT03001635 Jan 2017 → Dec 2018 myocardial infarction Sheba Medical Center Unknown No outcome recorded
Phase 2/3 NCT02888574 Nov 2016 → Dec 2018 chronic pain syndrome, pelvis syndrome University of Calgary Completed No outcome recorded
Phase 2/3 NCT02508103 Jul 2015 → Jun 2016 premenstrual dysphoric disorder University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 318 trials
Phase 3 NCT06010368 Oct 2024 → Dec 2025 overdue Cairo University Not yet recruiting No outcome recorded
Phase 3 NCT06725004 Jan → Dec 2023 female infertility, polycystic ovary syndrome Shakeela Ishrat Completed No outcome recorded
Phase 3 NCT04949633 Sep 2021 → Sep 2026 expected cervix disorder University Hospital, Tours Recruiting No outcome recorded
Phase 3 NCT04210310 Jan 2020 → May 2022 tinnitus NYU Langone Health Terminated No outcome recorded
Phase 3 NCT03640156 Jul 2018 → Dec 2019 autism spectrum disorder KU Leuven Completed No outcome recorded
Phase 3 NCT03339024 Nov 2017 → Mar 2019 alcohol dependence Norwegian University of Science and Technology Completed No outcome recorded
Phase 3 NCT02985749 Oct 2017 → Jan 2019 autism spectrum disorder 1 Massachusetts General Hospital Completed No outcome recorded
Phase 3 NCT02903251 Oct 2016 → Jan 2018 alcohol dependence Norwegian University of Science and Technology Completed No outcome recorded
Phase 3 NCT02794779 Jul 2016 → Dec 2017 Brasilia University Hospital Unknown No outcome recorded
Phase 3 NCT02618499 May → Nov 2016 Fundacion para la Salud Materno Infantil Terminated No outcome recorded
Phase 438 trials
Phase 4 NCT07636421 Aug 2026 → Apr 2028 expected uterine disorder Mansoura University Not yet recruiting No outcome recorded
Phase 4 NCT07566455 Aug 2025 → Feb 2026 CMH Multan Institute of Medical Sciences Completed No outcome recorded
Phase 4 NCT06990217 Jun 2025 → Jun 2027 expected HaEmek Medical Center, Israel Not yet recruiting No outcome recorded
Phase 4 NCT05823441 Jun 2023 → Jan 2024 Peking University People's Hospital Completed No outcome recorded
Phase 4 NCT05608070 Jun 2023 → Jun 2024 Beth Israel Deaconess Medical Center Withdrawn No outcome recorded
Phase 4 NCT05568745 Jan 2023 → Feb 2025 cervix disorder, preterm premature rupture of the membranes University Hospital, Clermont-Ferrand Unknown No outcome recorded
Phase 4 NCT05289869 Apr → Sep 2022 Ohio State University Completed No outcome recorded
Phase 4 NCT04760496 Oct 2021 → Dec 2024 obesity disorder Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 4 NCT03991091 Jan 2020 → Apr 2022 Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 4 NCT03749902 Jan 2020 → Jul 2022 University of Liverpool Completed No outcome recorded
Phase not applicable137 trials
NCT07687355 Jul → Oct 2026 expected Hayatabad Medical Complex Not yet recruiting No outcome recorded
NCT07559656 Apr → Sep 2026 expected University of Electronic Science and Technology of China Recruiting No outcome recorded
NCT07366359 Feb 2026 → Dec 2027 expected cervix disorder, preterm premature rupture of the membranes National Hospital of Obstetrics and Gynecology Recruiting No outcome recorded
NCT07425938 Jan → Apr 2026 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
NCT07318467 Jan → Jun 2026 overdue Cairo University Not yet recruiting No outcome recorded
NCT07162584 Sep 2025 → Jan 2026 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
NCT07006896 Jul 2025 → Jul 2026 overdue University of Pennsylvania Active not recruiting No outcome recorded
NCT06881459 Mar → Jul 2025 type 1 diabetes mellitus University Hospital, Gentofte, Copenhagen Completed No outcome recorded
NCT06605300 Oct 2024 → Jul 2025 University of Electronic Science and Technology of China Completed No outcome recorded
NCT07053930 Oct 2024 → Mar 2025 RESnTEC, Institute of Research Completed No outcome recorded
Show all 137 trials opens the full record — a long page
Also used as a comparator or background therapy in 224 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 08 trials
Phase 0 NCT05761860 Comparator Sep 2023 → Dec 2026 expected University of Florida Recruiting No outcome recorded
Phase 0 NCT04218409 Comparator Sep 2021 → Dec 2026 expected University of Florida Recruiting No outcome recorded
Phase 0 NCT04478942 Comparator Oct 2020 → Jan 2025 preterm premature rupture of the membranes University of Wisconsin, Madison Completed No outcome recorded
Phase 0 NCT04549012 Comparator Sep 2020 → Sep 2021 Ain Shams University Unknown No outcome recorded
Phase 0 NCT04089176 Comparator Feb → Apr 2019 Department of Medical Services Ministry of Public Health of Thailand Completed No outcome recorded
Phase 122 trials
Phase 1 NCT04789148 Comparator Sep 2025 → Jun 2026 overdue neurohypophyseal diabetes insipidus Elizabeth Austen Lawson Recruiting No outcome recorded
Phase 1 NCT04071119 Comparator Nov 2020 → Apr 2024 alcohol-related disorders Brown University Completed No outcome recorded
Phase 1 NCT04007224 Comparator Jan 2019 → Jun 2023 autism spectrum disorder Fundatia Bio-Forum Completed No outcome recorded
Phase 1 NCT03337035 Comparator Dec 2018 → Oct 2019 autism spectrum disorder Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT03390010 Comparator Dec 2017 → Feb 2018 Aljazeera Hospital Completed No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT05510310 Comparator Oct 2022 → Oct 2024 uterine disorder Western Galilee Hospital-Nahariya Unknown No outcome recorded
Phase 1/2 NCT03863288 Comparator Feb 2022 → Feb 2024 mood disorder University of Nebraska Terminated No outcome recorded
Phase 1/2 NCT04656067 Comparator Apr → Oct 2020 Egymedicalpedia Completed No outcome recorded
Phase 1/2 NCT04707950 Comparator Jan 2020 → Feb 2021 Benha University Unknown No outcome recorded
Phase 1/2 NCT03245762 Comparator Aug 2017 → Jan 2018 Prader-Willi syndrome University of Florida Completed No outcome recorded
Phase 223 trials
Phase 2 NCT06364228 Comparator Jun 2026 → May 2027 expected University of Nebraska Recruiting No outcome recorded
Phase 2 NCT06483659 Comparator Jun 2025 → Jul 2026 overdue Brigham and Women's Hospital Recruiting No outcome recorded
Phase 2 NCT06036004 Comparator Jan 2024 → Oct 2026 expected central diabetes insipidus University Hospital, Basel, Switzerland Recruiting No outcome recorded
Phase 2 NCT03878316 Comparator Jun 2022 → Oct 2023 alcohol abuse National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed No outcome recorded
Phase 2 NCT04117243 Comparator Jan → Dec 2020 Cairo University Completed No outcome recorded
Phase 2/36 trials
Phase 2/3 NCT06702670 Background Mar 2025 → Mar 2027 expected dystocia The University of Texas Health Science Center, Houston Recruiting No outcome recorded
Phase 2/3 NCT03878589 Comparator Aug 2019 → Dec 2024 osteoarthritis, knee University of Florida Completed No outcome recorded
Phase 2/3 NCT02786992 Comparator May 2016 → Jan 2020 Ain Shams University Completed No outcome recorded
Phase 2/3 NCT02007447 Comparator Jun → Aug 2015 autism spectrum disorder University of Sao Paulo General Hospital Terminated No outcome recorded
Phase 2/3 NCT02255357 Comparator Mar 2015 → Feb 2018 cocaine dependence New York State Psychiatric Institute Completed No outcome recorded
Phase 321 trials
Phase 3 NCT05245227 Background Jan 2025 → Jan 2027 expected Stony Brook University Recruiting No outcome recorded
Phase 3 NCT06514586 Comparator Sep 2024 → Jun 2025 overdue postmenopausal atrophic vaginitis, skin atrophy Oxagon Not yet recruiting No outcome recorded
Phase 3 NCT06259097 Comparator Jul 2024 → Jul 2026 overdue pregnancy disorder Icahn School of Medicine at Mount Sinai Enrolling by invitation No outcome recorded
Phase 3 NCT06325501 Comparator Mar → Dec 2024 leiomyoma Cairo University Unknown No outcome recorded
Phase 3 NCT03463993 Background Apr → Dec 2018 University of Zimbabwe Completed No outcome recorded
Phase 447 trials
Phase 4 NCT07688512 Comparator Aug 2026 → Aug 2028 expected uterine disorder Stony Brook University Not yet recruiting No outcome recorded
Phase 4 NCT07401524 Comparator May 2026 → Mar 2028 expected pregnancy disorder Sheba Medical Center Recruiting No outcome recorded
Phase 4 NCT07119398 Comparator Jul 2025 → Jul 2026 overdue preterm premature rupture of the membranes Eastern Virginia Medical School Recruiting No outcome recorded
Phase 4 NCT05782816 Comparator Apr 2023 → Dec 2024 The University of Texas Medical Branch, Galveston Completed No outcome recorded
Phase 4 NCT05806307 Comparator Mar → Oct 2023 drug pseudoallergy, uterine corpus leiomyoma Cairo University Unknown No outcome recorded
Phase not applicable89 trials
NCT07367672 Comparator Dec 2025 → Feb 2026 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
NCT07188207 Background Oct 2025 → Oct 2026 expected Assiut University Not yet recruiting No outcome recorded
NCT06930391 Comparator Sep 2025 → Jun 2026 overdue Samuel Lunenfeld Research Institute, Mount Sinai Hospital Recruiting No outcome recorded
NCT06333340 Comparator Jan 2025 → Dec 2026 expected Samuel Lunenfeld Research Institute, Mount Sinai Hospital Recruiting No outcome recorded
NCT07380529 Comparator Oct 2024 → Aug 2025 pregnancy disorder Ankara Etlik City Hospital Completed No outcome recorded

Evidence & citations 30 cited values

Every value below carries the sentence it was read from. 626 sources stand behind the page.

FieldValueCited text
Known as Oxytocin “This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure...” NCT03860233
596

“The role of oxytocin (OT) is already known in the regulation of satiety but some clinical studies demonstrated that OT participates also in the regulation of social behavior by...” NCT01038570

“This study will be carried out at Bangabandhu Sheikh Mujib Medical University (BSMMU) within six months after approval. This is a Randomized Control Trial which will compare...” NCT02396303

“one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution...” NCT03693599

“In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of...” NCT06060327

“Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24...” NCT02872467

“Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours” NCT03543917

“Intravenous oxytocin titration has a prime position as a choice agent for induction of labour following term PROM as it has been shown to be efficacious for such purpose.” NCT06343480

“Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.” NCT02044549

“nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)” NCT01325168

“intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse” NCT02229721

“Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session” NCT03225456

“The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)” NCT02336568

Oxytocin is a commonly used drug for IOL, especially in a favorable cervix.” NCT06372522

“accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV)” NCT02362945

Oxytocin intranasal spray is manufactured as the Syntocinon Nasal Spray.” NCT01834261

“Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.” NCT06036004

“Misoprostol, Dinoprostone, amniotomy, OxytocinNCT00385229

Oxytocin nasal spray for 5 days, 24 IU per day” NCT03610919

“Intranasal administration of 24 IU OxytocinNCT02501837

“Synthetic oxytocin spray, 24 IU per spray.” NCT04505904

“Syntocinon ampoules (10 IU Oxytocin).” NCT02053922

“Syntocinon (=Oxytocin), then Placebo” NCT03497988

“single dose of synthetic oxytocinNCT01216605

“TI-001 is intranasal oxytocinNCT01839149

“Administer IV 10 IU oxytocinNCT06413186

oxytocin nasal spray” NCT05664516

“Intranasal OxytocinNCT02149823

“Drug: OxytocinNCT03010670

“Drug: OxytocinNCT01719952

OxytocinNCT03096249

NCT07551882

NCT01576874

NCT04320706

NCT02918864

NCT01767025

NCT03081832

NCT01587625

NCT05899517

NCT02338089

NCT01012167

NCT03055546

NCT01039766

NCT04386447

NCT02098421

NCT02498236

NCT02028533

NCT02553226

NCT04789148

NCT01728909

NCT01530230

NCT01929161

NCT02745431

NCT05896553

NCT03119610

NCT01011465

NCT07687355

NCT01945957

NCT00257803

NCT02979093

NCT04025658

NCT02414503

NCT05093296

NCT02745522

NCT03084029

NCT03128242

NCT07409753

NCT07688512

NCT02079558

NCT01123317

NCT02568709

NCT02302430

NCT02051231

NCT02801227

NCT02503319

NCT04429880

NCT02680938

NCT01152047

NCT04493229

NCT01624194

NCT06881459

NCT04724187

NCT04747015

NCT01466127

NCT02276677

NCT05532501

NCT00490802

NCT05782816

NCT03597893

NCT01432470

NCT05892939

NCT00473707

NCT04656067

NCT01548521

NCT01566539

NCT02861482

NCT02526914

NCT03337035

NCT01631682

NCT03676621

NCT01081249

NCT04493515

NCT01571323

NCT07053930

NCT03408054

NCT02497547

NCT04105140

NCT02786992

NCT06364228

NCT00663039

NCT04492072

NCT00957593

NCT01849419

NCT04028765

NCT07053774

NCT03863288

NCT02775773

NCT02304055

NCT05383300

NCT01914939

NCT02405715

NCT03463993

NCT05432089

NCT02825641

NCT04413786

NCT01988649

NCT01699997

NCT06881810

NCT04946006

NCT02410655

NCT03085628

NCT03085654

NCT02251912

NCT01212185

NCT00919802

NCT05077540

NCT02941692

NCT01607970

NCT02101567

NCT02671266

NCT04629885

NCT03680339

NCT05096676

NCT06990217

NCT03749902

NCT05532215

NCT01788072

NCT05073939

NCT02304042

NCT02548728

NCT03710304

NCT03662425

NCT01973036

NCT04401839

NCT01573273

NCT01954186

NCT02595749

NCT01931033

NCT02720978

NCT05236985

NCT05467462

NCT02486822

NCT05273632

NCT02908126

NCT04089176

NCT01914419

NCT03578263

NCT02487797

NCT03254628

NCT01002300

NCT03168698

NCT02542813

NCT02903251

NCT01932060

NCT02702674

NCT02318121

NCT05037617

NCT03011307

NCT06285396

NCT04158167

NCT01712464

NCT03255148

NCT03829839

NCT02564068

NCT03033784

NCT02225600

NCT05511415

NCT05510310

NCT05608070

NCT01996605

NCT02465164

NCT02940574

NCT06285409

NCT02213029

NCT02737254

NCT03865615

NCT05920707

NCT03060031

NCT02762669

NCT02205034

NCT03651882

NCT07162584

NCT01944046

NCT01594775

NCT02859571

NCT04996498

NCT06757517

NCT06199076

NCT02393456

NCT02275611

NCT04109339

NCT02488642

NCT03001635

NCT01094028

NCT03335085

NCT01680718

NCT01065610

NCT04427709

NCT01886014

NCT01513499

NCT03892668

NCT02711189

NCT01093768

NCT04427540

NCT03991091

NCT03122067

NCT01712646

NCT07006896

NCT03591679

NCT07401524

NCT00116350

NCT02052258

NCT00540748

NCT02722356

NCT01549223

NCT02577575

NCT03006380

NCT03046836

NCT01211756

NCT01397630

NCT03425929

NCT02013258

NCT03278860

NCT03426176

NCT03846271

NCT05405257

NCT02191423

NCT01983514

NCT01711060

NCT02824627

NCT03016598

NCT01308749

NCT04906278

NCT00695331

NCT01912378

NCT02963194

NCT02682784

NCT02881177

NCT03265899

NCT05929339

NCT02063568

NCT01606462

NCT04143685

NCT06493968

NCT05207774

NCT02566356

NCT06605300

NCT05207436

NCT06469203

NCT03846505

NCT01517360

NCT03636555

NCT02737436

NCT02528136

NCT06194851

NCT03361124

NCT02156661

NCT01417026

NCT01608958

NCT03138252

NCT03144115

NCT03929367

NCT04228289

NCT05312008

NCT04177719

NCT00393731

NCT05289869

NCT02682888

NCT05290129

NCT00914953

NCT02723461

NCT04549012

NCT04218409

NCT06945926

NCT03001193

NCT03148574

NCT04903002

NCT04902729

NCT01412073

NCT02238379

NCT03148899

NCT01677364

NCT00977769

NCT06725004

NCT00481533

NCT05934812

NCT01190163

NCT02969447

NCT05672667

NCT03114371

NCT02255357

NCT01987804

NCT04176835

NCT03604874

NCT07559656

NCT03852797

NCT02301715

NCT06560099

NCT07119398

NCT04051619

NCT02121184

NCT03246919

NCT00844350

NCT02733237

NCT02391636

NCT02228031

NCT01335789

NCT02274454

NCT04715737

NCT03232918

NCT04105998

NCT03870503

NCT04431193

NCT02319707

NCT07366359

NCT05079841

NCT02080104

NCT02911272

NCT01963078

NCT05761860

NCT04431206

NCT03566069

NCT02350946

NCT03344302

NCT02144155

NCT02505984

NCT01614093

NCT03899597

NCT06405737

NCT01963091

NCT01139801

NCT02629991

NCT01252342

NCT03899961

NCT03819231

NCT02985749

NCT01710566

NCT07566455

NCT02183948

NCT06483659

NCT05760807

NCT02058251

NCT07367672

NCT04443647

NCT02485444

NCT04478942

NCT07636421

NCT02546570

NCT02567032

NCT04756661

NCT04738838

NCT06968481

NCT01780337

NCT01701180

NCT01869556

NCT02469259

NCT04595812

NCT02046499

NCT02911480

NCT04071119

NCT03211013

NCT03900754

NCT00790062

NCT06334172

NCT05806307

NCT02393443

NCT01236482

NCT01856530

NCT02441673

NCT06333340

NCT02303418

NCT03308643

NCT06189001

NCT02393144

NCT02647268

NCT02742532

NCT05664659

NCT00805662

NCT01568528

NCT03891095

NCT02306733

NCT02069431

NCT03434444

NCT00884897

NCT03238924

NCT00684606

NCT00200252

NCT01621737

NCT04210310

NCT06676774

NCT02187874

NCT04292444

NCT05265806

NCT02416583

NCT02273115

NCT01028677

NCT03414112

NCT02888574

NCT03245437

NCT04815395

NCT02210598

NCT02407340

NCT04435704

NCT03031405

NCT06808516

NCT02985086

NCT04017247

NCT01386333

NCT03610633

NCT01373359

NCT07318467

NCT05245227

NCT05245708

NCT04117243

NCT05568745

NCT05754073

NCT06010368

NCT01726478

NCT02999100

NCT07425938

NCT03577457

NCT06248710

NCT01752712

NCT03074409

NCT07436286

NCT02409862

NCT02302209

NCT01634854

NCT00263796

NCT02847143

NCT02804373

NCT04551482

NCT01394471

NCT02618096

NCT03011970

NCT02083809

NCT00989937

NCT04007224

NCT03282162

NCT03128203

NCT01823146

NCT07380529

NCT01296269

NCT01598623

NCT02954068

NCT03878589

NCT06514586

NCT04303702

NCT03428906

NCT01312272

NCT02223429

NCT03197662

NCT00813436

NCT00989027

NCT01254045

NCT03293511

NCT02090829

NCT03742531

NCT02508103

NCT06222749

NCT05745935

NCT03777878

NCT00776360

NCT01865669

NCT07188207

NCT00906347

NCT04760496

NCT02415920

NCT06550089

NCT04134663

NCT00787176

NCT06325501

NCT05444738

NCT03370510

NCT05742854

NCT03875391

NCT02794779

NCT04732247

NCT05341076

NCT04433741

NCT03957083

NCT05488457

NCT03228901

NCT05968651

NCT04890470

NCT00506909

NCT04201665

NCT03043053

NCT00120042

NCT04523922

NCT02741063

NCT03339024

NCT05627791

NCT02983591

NCT04137432

NCT06651476

NCT06332066

NCT02684305

NCT01827124

NCT01239888

NCT06930391

NCT03136263

NCT02562300

NCT05179421

NCT01937013

NCT03245762

NCT03140488

NCT02091817

NCT00777166

NCT01689298

NCT01689311

NCT02888041

NCT01827332

NCT05823441

NCT06181396

NCT00785395

NCT04949633

NCT01337687

NCT00890630

NCT05479357

NCT05251610

NCT01863706

NCT04518176

NCT02618499

NCT05340205

NCT06889155

NCT03937401

NCT00468520

NCT07430228

NCT01243658

NCT03395730

NCT02221830

NCT05083910

NCT05298085

NCT01908205

NCT03755531

NCT02602301

NCT04306354

NCT03172858

NCT01382732

NCT02361177

NCT02127073

NCT07140237

NCT06141447

NCT02314728

NCT02100956

NCT03640156

NCT04307069

NCT03878316

NCT04330677

NCT00784797

NCT00984347

NCT01256060

NCT02740101

NCT03935399

NCT01600612

NCT02652195

NCT02689596

NCT00975416

NCT01722071

NCT03272321

NCT03846739

NCT01829516

NCT07093060

NCT05865288

NCT04707950

NCT01939639

NCT01551303

NCT00891150

NCT03183674

NCT03593473

NCT05864508

NCT02710084

NCT02443727

NCT02493426

NCT02495272

NCT03486925

Known as d5OT “A single, 1 International Unit (IU) bolus of deuterated oxytocin (d5OT) will be given to the subject” NCT05488457
Known as deuterated oxytocin “A single, 1 International Unit (IU) bolus of deuterated oxytocin (d5OT) will be given to the subject” NCT05488457
Known as GR121619 “A Single Centre, Single Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin (GR121619) Administered Via an Inhaled Route in...” NCT02542813
Known as IN-OXT “intranasal oxytocin (IN-OXT) vs. placebo” NCT02629991
3

“Intranasal Oxytocin (IN-OXT)” NCT06605300

“Intranasal Oxytocin (IN-OXT)” NCT04789148

“Intranasal Oxytocin (IN-OXT)” NCT07551882

Known as Inj. Linda “The participants in experimental group will receive inj. (injection) oxytocin 10 IU (Inj. Linda 10 unit, Nuvista Pharmaceuticals Limited) intramuscular as trigger” NCT06725004
Known as Ocytocin ClinicalTrials.gov intervention name — accepted as the source's own label NCT04046510
Known as OCYTOCINA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02007447
Known as OXT “The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development. To this end, the...” NCT02505984
20

“The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with...” NCT03370510

“Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03428906

“Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03891095

“Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03597893

“Oxytocin (OXT), a neuropeptide closely associated with AVP in terms of anatomical location and function, is known to play a critical role in social, emotional, and behavioral...” NCT06808516

“Endogenous oxytocin (OXT) has been a focus of prior psychiatric research due to its role in pro-social behavior, and modulation of response to social/emotional stimuli.” NCT03863288

“Emerging evidence suggests that the neuropeptide oxytocin (OXT) may be a blood-based biomarker of social functioning and a possible treatment for ASD.” PMID 28696286 Jul 2017

“The neuropeptide oxytocin (OXT) may facilitate social interactions either by increasing their rewarding experience or by attenuating anxiety” PMID 30086408 Aug 2018

“Oxytocin (OXT), a neuropeptide involved in social cognition, is a potential therapeutic agent for alleviating social dysfunction.” PMID 33587397 Mar 2021

“The hypothalamic peptide oxytocin (OXT) has anxiolytic effects both in healthy participants and patients with anxiety disorders” NCT03829839

“One promising candidate to reduce stress and improve quality of life is the endogenous neuropeptide oxytocin (OXT).” NCT06364228

“The neuropeptide oxytocin (OXT) exerts anxiolytic and anti-stress effects in visual and auditory modalities” NCT03265899

“The neuropeptide oxytocin (OXT) has been shown to modulate several aspects of human social cognition.” NCT02183948

“ASD is also characterized by low levels of oxytocin (OXT), a peptide hormone with prosocial effects.” NCT05754073

“hypothalamic neuropeptide Oxytocin (OXT) may modulate attention allocation and regulation” NCT03486925

“the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making” NCT04890470

“Oxytocin (OXT), as a neuropeptide, plays a role in emotional and social behaviors.” PMID 32082606 Feb 2020

“the neuropeptide oxytocin (OXT) influences self-processing” NCT02963194

“Oxytocin (OXT) is an important prosocial peptide” NCT01699997

“the neuropeptide oxytocin (OXT)” NCT04330677

Known as OXY “One potential compound is oxytocin (OXY), which proved beneficial effects on alcohol craving and stress reactivity in preliminary clinical studies and synergism with NTX effects.” PMID 35410938 Apr 2022
Known as OXYTIP “Oxytocin (OXYTIP; manufactured by IPDIC, Rasht, Iran), 5 IU and hCG (Choriomon; manufactured by IBSA Institute Biochimique SA, CH-6903 Lugano), 5000 IU were also administrated...” NCT00844350
Known as Oxytocin (Syntocinon) Oxytocin (Syntocinon)NCT02205034
Known as Oxytocin Grindeks Oxytocin Grindeks 10 IU/ml- solution for injection” NCT06990217
Known as Oxytocin: Syntocinon Nasal Spray Oxytocin: Syntocinon Nasal SprayNCT01566539
Known as Oxytocin: Syntocinon-Spray, Novartis Oxytocin: Syntocinon-Spray, NovartisNCT01607970
2

Oxytocin: Syntocinon-Spray, NovartisNCT01701180

Oxytocin: Syntocinon-Spray, NovartisNCT01606462

Known as Pitocin “they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which...” NCT02595749
14

“A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant.” NCT03819231

“Prior literature has examined the use of Pitocin (Oxytocin), vaginal and oral misoprostol, and dinoprost with mixed results.” NCT04028765

“The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl” NCT02684305

“up titration of Pitocin if contractions are inadequate” NCT06702670

“10 IU oxytocin (Pitocin) for intramuscular injection” NCT03935399

“Intramuscular injection of Oxytocin (Pitocin®)” NCT04427709

“Oxytocin (also: syntocinon, pitocin)” NCT00813436

“oxytocin (Pitocin)” NCT00914953

NCT01736852

NCT01615107

NCT02910115

NCT06259097

NCT02150954

NCT05326776

Known as RVG 03716 “Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716)” NCT04443647
Known as Synpitan forte “Group II: Oxytocin(Synpitan forte®; Deva Pharma, Istanbul, Turkey)” NCT05467462
1

“Group I: Oxytocin(Synpitan forte®; Deva Pharma, Istanbul, Turkey)” NCT05083910

Known as synthetic oxytocin “Syntocinon (synthetic oxytocin)” NCT02090829
Known as syntocinon “An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one...” NCT03892668
45

“Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day...” NCT04903002

Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24...” NCT02872467

“In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of...” NCT06060327

“Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been...” NCT01719952

“OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal...” PMID 25503617 Dec 2014

“10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.” NCT06889155

“Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.” NCT04201665

“Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).” NCT02443727

“participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).” NCT02393443

“Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).” NCT02303418

“Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution” NCT03395730

“oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland)” NCT05806307

“20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)” NCT05077540

Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration” NCT03096249

“The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray.” NCT03114371

“FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days” NCT01712464

“the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon.” NCT00884897

“Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session” NCT03225456

“100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon®, Novartis, Switzerland).” NCT02306733

“participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals).” NCT02393456

“following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14” NCT02350946

“group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).” NCT02304055

“Group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland)” NCT02304042

Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716)” NCT04443647

Syntocinon (synthetic oxytocin) will be used in this protocol.” NCT03197662

“followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary)” NCT02888041

“Intranasal oxytocin (Syntocinon; Novartis, Switzerland)” NCT02888574

Syntocinon® (synthetic oxytocin) to induce labour” NCT02553226

“Oxytocin (also: syntocinon, pitocin)” NCT00813436

Syntocinon (Oxytocin) nasal spray” NCT01594775

Syntocinon (Oxytocin)” NCT02940574

SyntocinonNCT02985749

NCT03497988

NCT03390010

NCT00963040

NCT01066299

NCT03252496

NCT05215873

NCT03260920

NCT02508220

NCT02216383

NCT02849743

NCT02053922

NCT05110482

NCT01183221

Known as Syntocinon nasal spray “A single dose of 80 I.U. oxytocin in aerosol form (Syntocinon® nasal spray) is administered via 20 puffs 2 times per week intranasally.” NCT06881810
4

“Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)” NCT03136263

“Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks” NCT01308749

“Oxytocin intranasal spray is manufactured as the Syntocinon Nasal Spray.” NCT01834261

NCT06881810

Known as Syntocinon-spray “Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)” NCT03891095
1

“Oxytocin: Syntocinon-Spray, Novartis” NCT02156661

Known as TI-001 TI-001 is intranasal oxytocin” NCT01839149
Known as TNX-1900 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05679908
Known as TTA-121 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03466671